• Colgate-Palmolive’s second-quarter 2026 results showed sales rising to US$5,361 million from US$5,110 million a year earlier, while net income and earnings per share eased, and the company kept its full-year 2026 outlook for 2% to 6% net sales growth and double-digit GAAP EPS growth.
• The combination of higher sales but softer profitability, alongside management’s decision to maintain guidance despite ongoing cost and margin pressures, highlights a focus on sustaining growth while absorbing input and logistics headwinds across key regions.
• We’ll now examine how maintaining full-year earnings guidance despite margin pressure could influence Colgate-Palmolive’s existing investment narrative and outlook.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Colgate-Palmolive Investment Narrative Recap

To remain a Colgate-Palmolive shareholder, you need to believe in the durability of its global oral care and pet nutrition brands and their ability to support steady cash generation. The latest quarter showed modest sales growth but softer earnings, and management’s decision to keep full year sales and EPS guidance intact suggests the near term catalyst of consistent earnings delivery is unchanged, while margin pressure from higher input and logistics costs remains the biggest risk.

The most relevant recent announcement is Colgate-Palmolive’s reaffirmed 2026 outlook for 2% to 6% net sales growth and double digit GAAP EPS growth. Holding this guidance after reporting lower net income and EPS underlines the tension between the company’s growth ambitions and ongoing cost inflation, which could matter for how investors weigh its emerging markets and premiumization catalysts against the risk of prolonged margin compression.

Yet behind resilient guidance, investors should still be aware of how rising raw material and packaging costs could...

Colgate-Palmolive's narrative projects $22.8 billion revenue and $3.5 billion earnings by 2029. This requires 3.8% yearly revenue growth and a $1.4 billion earnings increase from $2.1 billion today.

Uncover how Colgate-Palmolive's forecasts yield a $96.68 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates for Colgate-Palmolive span roughly US$96.68 to US$126.19 per share, showing how far views can diverge. As you weigh these, remember that persistent raw material and logistics cost pressures could influence how comfortably the company can support its growth plans and profitability over time, so it is worth comparing several perspectives before forming your own view.

Explore 3 other fair value estimates on Colgate-Palmolive - why the stock might be worth as much as 38% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Colgate-Palmolive research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.